disopyramide has been researched along with Torsade de Pointes in 13 studies
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Disopyramide was metabolized by the cytochrome enzyme CYP3A4 and clarithromycin competitively inhibits this enzyme, probably resulting in an increase in plasma concentration of disopyramide." | 5.30 | Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. ( Hashimoto, T; Hayashi, Y; Ikeda, U; Mitsuhashi, T; Shimada, K; Watanabe, T, 1999) |
| "Initiation of disopyramide in the outpatient setting is safe and the risk of subsequent sudden cardiac death is low." | 1.46 | Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients. ( Adler, A; Chan, RH; Fourey, D; Gollob, MH; Hindieh, W; Rakowski, H; Weissler-Snir, A, 2017) |
| "Disopyramide was metabolized by the cytochrome enzyme CYP3A4 and clarithromycin competitively inhibits this enzyme, probably resulting in an increase in plasma concentration of disopyramide." | 1.30 | Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. ( Hashimoto, T; Hayashi, Y; Ikeda, U; Mitsuhashi, T; Shimada, K; Watanabe, T, 1999) |
| "Episodes of torsade de pointes frequently occur after a prolonged pause." | 1.29 | Quinidine but not disopyramide prolongs cardiac Purkinje fiber action potentials after a pause. ( Bursill, JA; Campbell, TJ; Wyse, KR, 1994) |
| "Torsades de pointes was induced following ventricular paced beats and suppressed by cessation of disopyramide in all or by setting a higher pacing rate in one." | 1.29 | Torsades de pointes in paced patients with sick sinus syndrome after disopyramide administration. ( Fujito, T; Hayashi, T; Inoue, T; Kimura, Y; Morooka, S; Sakai, Y; Satoh, T; Takabatake, Y; Takayanagi, K, 1994) |
| " This complexity seems to be the most important reason for the limited reliability of serum concentration measurements for predicting the best dosage for the individual patient." | 1.28 | [Torsades de pointes ventricular tachycardia induced by disopyramide at therapeutic serum concentration]. ( Aarskog, D; Reikvam, A, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (53.85) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kramer, J | 1 |
| Obejero-Paz, CA | 1 |
| Myatt, G | 1 |
| Kuryshev, YA | 1 |
| Bruening-Wright, A | 1 |
| Verducci, JS | 1 |
| Brown, AM | 1 |
| Adler, A | 1 |
| Fourey, D | 1 |
| Weissler-Snir, A | 1 |
| Hindieh, W | 1 |
| Chan, RH | 1 |
| Gollob, MH | 1 |
| Rakowski, H | 1 |
| Hirose, K | 1 |
| Yamaguchi, H | 1 |
| Oshima, Y | 1 |
| Choraku, M | 1 |
| Hirono, A | 1 |
| Takamori, N | 1 |
| Tamura, K | 1 |
| Matsuhashi, T | 1 |
| Sato, T | 1 |
| Aizawa, Y | 1 |
| Takatsuki, S | 1 |
| Miyamoto, K | 1 |
| Kawai, H | 1 |
| Aoyama, R | 1 |
| Watanabe, H | 1 |
| Suzuki, K | 1 |
| Suga, N | 1 |
| Kitagawa, W | 1 |
| Miura, N | 1 |
| Nishikawa, K | 1 |
| Imai, H | 1 |
| Asajima, H | 1 |
| Saito, N | 1 |
| Ohmura, Y | 1 |
| Ohmura, K | 1 |
| Bursill, JA | 1 |
| Wyse, KR | 1 |
| Campbell, TJ | 1 |
| Kimura, Y | 1 |
| Takayanagi, K | 1 |
| Sakai, Y | 1 |
| Satoh, T | 1 |
| Fujito, T | 1 |
| Inoue, T | 1 |
| Hayashi, T | 1 |
| Morooka, S | 1 |
| Takabatake, Y | 1 |
| Makkar, RR | 1 |
| Fromm, BS | 1 |
| Steinman, RT | 1 |
| Meissner, MD | 1 |
| Lehmann, MH | 1 |
| Kurita, T | 2 |
| Ohe, T | 2 |
| Shimizu, W | 2 |
| Suyama, K | 1 |
| Aihara, N | 1 |
| Takaki, H | 1 |
| Kamakura, S | 1 |
| Shimomura, K | 2 |
| Hayashi, Y | 1 |
| Ikeda, U | 1 |
| Hashimoto, T | 1 |
| Watanabe, T | 1 |
| Mitsuhashi, T | 1 |
| Shimada, K | 1 |
| Aarskog, D | 1 |
| Reikvam, A | 1 |
| Emori, T | 1 |
1 review available for disopyramide and Torsade de Pointes
| Article | Year |
|---|---|
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Bepridil; Cardiovascular Agents; Disopyramid | 1993 |
12 other studies available for disopyramide and Torsade de Pointes
| Article | Year |
|---|---|
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp T | 2013 |
Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients.
Topics: Action Potentials; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Data | 2017 |
Severe respiratory failure and torsades de pointes induced by disopyramide in a patient with myasthenia gravis.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cholinergic Antagonists; Disopyramide; Electrocardiogra | 2008 |
Recurrent Torsade de Pointes during mild hypothermia therapy for a survivor of sudden cardiac arrest due to drug-induced long-QT syndrome.
Topics: Aged; Anti-Arrhythmia Agents; Disopyramide; Female; Heart Arrest; Humans; Hypothermia, Induced; Long | 2010 |
Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Cytochrome P-450 CYP3A; Disopyrami | 2010 |
Lansoprazole precipitated QT prolongation and torsade de pointes associated with disopyramide.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Arrhythmia Agents; Anti-Ulcer Agents; Disopyrami | 2012 |
Quinidine but not disopyramide prolongs cardiac Purkinje fiber action potentials after a pause.
Topics: Action Potentials; Animals; Disopyramide; Dogs; Dose-Response Relationship, Drug; Electrodes, Implan | 1994 |
Torsades de pointes in paced patients with sick sinus syndrome after disopyramide administration.
Topics: Aged; Cardiac Pacing, Artificial; Disopyramide; Electrocardiography; Female; Humans; Potassium; Sick | 1994 |
Early afterdepolarizationlike activity in patients with class IA induced long QT syndrome and torsades de pointes.
Topics: Action Potentials; Aged; Anti-Arrhythmia Agents; Disopyramide; Electrocardiography; Electrophysiolog | 1997 |
Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia.
Topics: Aged; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Arrhythmias, Cardiac; Clarithromycin; Cytochrom | 1999 |
[Torsades de pointes ventricular tachycardia induced by disopyramide at therapeutic serum concentration].
Topics: Aged; Disopyramide; Female; Humans; Torsades de Pointes | 1992 |
Induction of TU abnormalities in patients with torsades de pointes.
Topics: Action Potentials; Adolescent; Aged; Disopyramide; Electrocardiography; Female; Heart Conduction Sys | 1992 |